AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-17 (cancelled).

Claim 18 (currently amended): A solid pharmaceutical composition comprising a therapeutically and/or prophylactically effective amount of **[[a drug]]** **celecoxib** and a dispersion-enhancing amount of an effervescent agent, wherein (a) the dosage form is adapted for swallowing without prior disintegration in water or in the mouth, and (b) the amount of the effervescent agent is not sufficient to substantially enhance disintegration of the dosage form in an aqueous medium.

Claim 19 (cancelled).

Claim 20 (currently amended): The composition of Claim 18 wherein the rate of dissolution of the **[[drug]]** **celecoxib** in an aqueous medium is enhanced.

Claim 21 (original): The composition of Claim 18 wherein the effervescent agent generates oxygen or carbon dioxide gas upon contact with water.

Claim 22 (original): The composition of Claim 18 that is a dosage form selected from the group consisting of a tablet, a caplet, a capsule, a drug powder and a powder blend.

Claim 23 (original): The composition of Claim 18 wherein the effervescent agent comprises an acid component and a base component.

Claim 24 (original): The composition of Claim 23 wherein the acid component comprises at least one acid selected from the group consisting of citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides and acid salts thereof, and mixtures thereof.

Claim 25 (original): The composition of Claim 24 wherein the at least one acid is citric acid.

Claim 26 (original): The composition of Claim 23 wherein the base component comprises at least one base selected from the group consisting of carbonate salts, bicarbonate salts, sesquicarbonate salts, and mixtures thereof.

Claim 27 (original): The composition of Claim 26 wherein the at least one base is calcium carbonate.

Claim 28 (original): The composition of Claim 23 wherein the weight ratio of the acid component to the base component in the effervescent agent is about 1:100 to about 100:1.

Claim 29 (original): The composition of Claim 23 wherein the weight ratio of the acid component to the base component in the effervescent agent is about 1:50 to about 50:1.

Claim 30 (original): The composition of Claim 23 wherein the weight ratio of the acid component to the base component in the effervescent agent is about 1:10 to about 10:1.

Claim 31 (original): The composition of Claim 23 wherein the ratio of the acid component to the base component in the effervescent agent is approximately stoichiometric.

Claim 32 (original): The composition of Claim 18 wherein the effervescent agent is present in the composition in an amount of about 1% to about 20% by weight.

Claim 33 (original): The composition of Claim 18 wherein the effervescent agent is present in the composition in an amount of about 2% to about 15% by weight.

Claim 34 (original): The composition of Claim 18 wherein the effervescent agent is present in the composition in an amount of about 3% to about 10% by weight.

Claim 35 (currently amended): A solid pharmaceutical dosage form comprising a therapeutically and/or prophylactically effective amount of **[[a drug]]** **celecoxib** and a dispersion-enhancing amount of an effervescent agent, wherein the dosage form does not exceed about 800 mg in total weight.

Claim 36 (original): The dosage form of Claim 35 wherein said dosage form has a total weight of about 100 to about 750 mg.

Claim 37 (original): The dosage form of Claim 35 wherein said dosage form has a total weight of about 200 to about 700 mg.

Claim 38 (cancelled).

Claim 39 (currently amended): The composition of Claim 35 wherein the rate of dissolution of the **[[drug]]** **celecoxib** in an aqueous medium is enhanced.

Claim 40 (original): The composition of Claim 35 wherein the effervescent agent generates oxygen or carbon dioxide gas upon contact with water.

Claim 41 (original): The composition of Claim 35 that is a dosage form selected from the group consisting of a tablet, a caplet, a capsule, a drug powder and a powder blend.

Claim 42 (original): The composition of Claim 35 wherein the effervescent agent comprises an acid component and a base component.

Claim 43 (original): The composition of Claim 42 wherein the acid component comprises at least one acid selected from the group consisting of citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides and acid salts thereof, and mixtures thereof.

Claim 44 (original): The composition of Claim 43 wherein the at least one acid is citric acid.

Claim 45 (original): The composition of Claim 42 wherein the base component comprises at least one base selected from the group consisting of carbonate salts, bicarbonate salts, sesquicarbonate salts, and mixtures thereof.

Claim 46 (original): The composition of Claim 45 wherein the at least one base is calcium carbonate.

Claim 47 (original): The composition of Claim 42 wherein the weight ratio of the acid component to the base component in the effervescent agent is about 1:100 to about 100:1.

Claim 48 (original): The composition of Claim 42 wherein the weight ratio of the acid component to the base component in the effervescent agent is about 1:50 to about 50:1.

Claim 49 (original): The composition of Claim 42 wherein the weight ratio of the acid component to the base component in the effervescent agent is about 1:10 to about 10:1.

Claim 50 (original): The composition of Claim 42 wherein the ratio of the acid component to the base component in the effervescent agent is approximately stoichiometric.

Claim 51 (original): The composition of Claim 35 wherein the effervescent agent is present in the composition in an amount of about 1% to about 20% by weight.

Claim 52 (original): The composition of Claim 35 wherein the effervescent agent is present in the composition in an amount of about 2% to about 15% by weight.

Claim 53 (original): The composition of Claim 35 wherein the effervescent agent is present in the composition in an amount of about 3% to about 10% by weight.

Claims 54-61 (Cancelled).